⌘K

Galecto, Inc. (GLTO)

$12.85 -0.62% $-0.08 Healthcare

Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is based in Boston, Massachusetts.

Market cap

$13.94M

CEO

Dr. Hans T. Schambye M.D., Ph.D.

Full time employees

40.00

Headquarters

Boston, MA

IPO Date

Oct 29, 2020

Price-to-earnings (PE) Ratio

-0.55

Earnings-per-share (EPS)

$-23.25

Cash ratio (TTM)

4.88

Current ratio (TTM)

7.07

Net profit margin (TTM)

-2,565.06%

PE ratio (TTM)

-0.48

PEG ratio (TTM)

-0.09

Price-to-book ratio (TTM)

0.53

Price-to-sales ratio (TTM)

12.30

Quick ratio (TTM)

6.69

Return on assets (TTM)

-94.93%

Return on equity (TTM)

-87.11%

Similar stocks (15)

Revolution Medicines, Inc.

RVMD

$44.54 1.92% $0.84

Neutral

Edgewise Therapeutics, Inc.

EWTX

$16.86 -10.46% $-1.97

Neutral

Day One Biopharmaceuticals, Inc.

DAWN

$13.63 -3.54% $-0.50

Downtrend

Cullinan Oncology, Inc.

CGEM

$16.93 -5.68% $-1.02

Uptrend

Terns Pharmaceuticals, Inc.

TERN

$9.41 5.08% $0.46

Uptrend

Monte Rosa Therapeutics, Inc.

GLUE

$5.62 -7.57% $-0.46

Neutral

Lyell Immunopharma, Inc.

LYEL

$1.24 0.81% $0.01

Downtrend

Acrivon Therapeutics, Inc. Common Stock

ACRV

$8.23 -7.63% $-0.68

Uptrend

Amylyx Pharmaceuticals, Inc.

AMLX

$2.65 1.14% $0.03

Downtrend

Acumen Pharmaceuticals, Inc.

ABOS

$2.54 -2.31% $-0.06

Downtrend

Coherus BioSciences, Inc.

CHRS

$1.05 -19.23% $-0.25

Downtrend

Aligos Therapeutics, Inc.

ALGS

$14.22 -3.92% $-0.58

Downtrend

Spero Therapeutics, Inc.

SPRO

$1.37 0.00% $0.00

Downtrend

Aadi Bioscience, Inc.

AADI

$1.88 4.44% $0.08

Downtrend

Bolt Biotherapeutics, Inc.

BOLT

$0.64 3.99% $0.02

Downtrend

ETF Exposure (2)

Vanguard Extended Market Index Fund Institutional Shares

VIEIX

$134.52 1.86% $2.45

Uptrend

Vanguard Extended Market Index Fund

VXF

$178.36 0.55% $0.97

Uptrend

Downtrend

Similar stocks (15)

Revolution Medicines, Inc.

RVMD

$44.54 1.92% $0.84

Neutral

Edgewise Therapeutics, Inc.

EWTX

$16.86 -10.46% $-1.97

Neutral

Day One Biopharmaceuticals, Inc.

DAWN

$13.63 -3.54% $-0.50

Downtrend

Cullinan Oncology, Inc.

CGEM

$16.93 -5.68% $-1.02

Uptrend

Terns Pharmaceuticals, Inc.

TERN

$9.41 5.08% $0.46

Uptrend

Monte Rosa Therapeutics, Inc.

GLUE

$5.62 -7.57% $-0.46

Neutral

Lyell Immunopharma, Inc.

LYEL

$1.24 0.81% $0.01

Downtrend

Acrivon Therapeutics, Inc. Common Stock

ACRV

$8.23 -7.63% $-0.68

Uptrend

Amylyx Pharmaceuticals, Inc.

AMLX

$2.65 1.14% $0.03

Downtrend

Acumen Pharmaceuticals, Inc.

ABOS

$2.54 -2.31% $-0.06

Downtrend

Coherus BioSciences, Inc.

CHRS

$1.05 -19.23% $-0.25

Downtrend

Aligos Therapeutics, Inc.

ALGS

$14.22 -3.92% $-0.58

Downtrend

Spero Therapeutics, Inc.

SPRO

$1.37 0.00% $0.00

Downtrend

Aadi Bioscience, Inc.

AADI

$1.88 4.44% $0.08

Downtrend

Bolt Biotherapeutics, Inc.

BOLT

$0.64 3.99% $0.02

Downtrend

ETF Exposure (2)

Vanguard Extended Market Index Fund Institutional Shares

VIEIX

$134.52 1.86% $2.45

Uptrend

Vanguard Extended Market Index Fund

VXF

$178.36 0.55% $0.97

Uptrend